| Autor: |
Tomita, Eiichi, Ando, Kazuki, Sugihara, Jun-ichi, Nishigaki, Youichi, Yamada, Tetsuya, Ando, Ryoko, Takemura, Masao, Seishima, Mitsuru |
| Předmět: |
|
| Zdroj: |
Hepatology Research; Mar2010, Vol. 40 Issue 3, p261-268, 8p, 1 Diagram, 2 Charts, 2 Graphs |
| Abstrakt: |
Aim: Although interferon (IFN)/ribavirin is the mainstream combination treatment for chronic hepatitis C in patients with a high viral load, ribavirin is problematic for women of childbearing age and patients with anemia. Therefore we needed to establish a new regimen without ribavirin. Methods: We devised a new regimen (same-day β/α2b) to administer IFN-β and α2b on the same-day, and compared it with IFN-α2b alone and IFN-α2b plus ribavirin. The cases were 36 patients (26.1%) in whom ribavirin could not be used (young women, anemia, etc.) among 138 patients who underwent IFN treatment after ribavirin release. Results: The percentages of patients withdrawing due to side-effects were 6.8%, 18.8% and 17.0% in the treatment with same-day β/α2b, IFN-α2b alone and IFN-α2b plus ribavirin groups, respectively. In genotype 1b, the sustained viral response (SVR) was 28.6% (4/14), 13.6% (3/22) and 25.0% (8/32) with a high viral load, and 91.7% (11/12), 27.3% (3/11) and 57.1% (4/7) with a low viral load for the respective groups. According to a study on viral half-life during the early phase of IFN therapy, there was no difference among the regimens of same-day IFN-β/α2b, β alone, α2b alone and twice-daily treatment with IFN-β. Same-day β/α2b treatment showed a significantly higher SVR rate in moving type patients with a genotype 1b/high viral load. Conclusions: Same-day β/α2b treatment resulted in few cases where therapy was discontinued and showed a high SVR rate. This regimen is especially appropriate in cases where ribavirin has been deemed unsuitable. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
